AU2001255495A1 - Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection - Google Patents

Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection

Info

Publication number
AU2001255495A1
AU2001255495A1 AU2001255495A AU5549501A AU2001255495A1 AU 2001255495 A1 AU2001255495 A1 AU 2001255495A1 AU 2001255495 A AU2001255495 A AU 2001255495A AU 5549501 A AU5549501 A AU 5549501A AU 2001255495 A1 AU2001255495 A1 AU 2001255495A1
Authority
AU
Australia
Prior art keywords
rnain
ribavirin
infection
patients
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255495A
Inventor
Frank Bennett
Ashit K. Ganguly
Viyyoor M. Girijavallabhan
Raymond G. Lovey
Jinping Mccormick
Anil K. Saksena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2001255495A1 publication Critical patent/AU2001255495A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
AU2001255495A 2000-04-20 2001-04-18 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection Abandoned AU2001255495A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19880100P 2000-04-20 2000-04-20
US60198801 2000-04-20
PCT/US2001/012760 WO2001081359A1 (en) 2000-04-20 2001-04-18 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
AU2001255495A1 true AU2001255495A1 (en) 2001-11-07

Family

ID=22734903

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255495A Abandoned AU2001255495A1 (en) 2000-04-20 2001-04-18 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection

Country Status (5)

Country Link
US (2) US6924270B2 (en)
EP (1) EP1282632A1 (en)
AR (1) AR031572A1 (en)
AU (1) AU2001255495A1 (en)
WO (1) WO2001081359A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (en) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед APPLICATION OF RIBONOUSALIC COMPOUNDS FOR TREATING FLAVIVIRUS AND PESTIVIRUS INFECTIONS
US20060024270A1 (en) * 2000-08-23 2006-02-02 The New York Hospital Medical Center Of Queens Compositions and methods for preventing or treating encephalitis with interferon
HUP0301444A3 (en) * 2000-10-18 2007-05-29 Schering Corp The use of ribavirin-pegylated interferon alfa for the preparation of pharmaceutical compositions for the treatment of hcv infection
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0312278A (en) * 2002-06-28 2007-06-19 Idenix Cayman Ltd 2'-c-methyl-3'-o-1-valine ribofuranosyl cytidine ester for treatment of flaviviridae infections
JP2005533817A (en) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド Modified 2 'and 3'-nucleoside prodrugs for the treatment of Flaviviridae virus infection
US8476254B2 (en) 2002-07-02 2013-07-02 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferson-α therapy
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
AU2003300901A1 (en) * 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
AU2003300434A1 (en) * 2002-12-23 2004-07-22 Idenix (Cayman) Limited Process for the production of 3'-nucleoside prodrugs
ES2726998T3 (en) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Modified fluorinated nucleoside analogs
ATE388963T1 (en) 2003-08-07 2008-03-15 Zymogenetics Inc HOMOGENEOUS PRODUCTIONS OF IL-29
US20070202078A1 (en) * 2003-08-13 2007-08-30 Smith Howard J Method Of Treating Viral Infections
CA2537849A1 (en) * 2003-09-11 2005-03-17 F. Hoffmann-La Roche Ag Process for preparing antiviral nucleoside derivatives
WO2005097165A2 (en) 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
US20060040944A1 (en) * 2004-06-23 2006-02-23 Gilles Gosselin 5-Aza-7-deazapurine derivatives for treating Flaviviridae
PT3109244T (en) 2004-09-14 2019-06-04 Gilead Pharmasset Llc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CA2583026A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
EP1951748B1 (en) 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7781576B2 (en) * 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JP5793084B2 (en) 2008-12-23 2015-10-14 ギリアド ファーマセット エルエルシー Synthesis of purine nucleosides
BRPI0922508A8 (en) 2008-12-23 2016-01-19 Pharmasset Inc NUCLEOSID ANALOGS
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CN102858790A (en) 2010-03-31 2013-01-02 吉利德制药有限责任公司 Nucleoside Phosphoramidates
EP2585065A1 (en) 2010-06-24 2013-05-01 Panmed Ltd. Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
AU2011311706B2 (en) 2010-10-05 2015-11-12 Debiopharm S.A. New treatments of Hepatitis C virus infection
BR112013013166A2 (en) * 2010-11-30 2016-09-06 Novartis Ag hepatitis c virus infection treatments
PT3042910T (en) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-spiro-nucleosides for use in the therapy of hepatitis c
BR112013025021A2 (en) 2011-03-31 2017-03-01 Novartis Ag alisporivir to treat hepatitis virus infections c.
MX2013011941A (en) 2011-04-13 2014-05-28 Debiopharm Int Sa Treatment of hepatitis c virus infection with alisporivir.
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
SG10201602044WA (en) 2011-09-16 2016-04-28 Gilead Pharmassett Llc Methods For Treating HCV
BR112014007247A2 (en) * 2011-09-27 2017-03-28 Novartis Ag alisporivir for the treatment of hepatitis C virus infection
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2852867C (en) 2013-01-31 2016-12-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
MX2016002185A (en) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Combination formulation of two antiviral compounds.
CN111320662B (en) * 2020-02-17 2022-11-25 南京医科大学 N-benzyl substituted diamidinonazine derivative and pharmaceutical application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
GB1482736A (en) 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US5674911A (en) 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US4925930A (en) 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
JPH07503851A (en) * 1992-02-10 1995-04-27 インターフェロン・サイエンシズ、インコーポレイテッド Improved interferon and its production method from human peripheral blood leukocytes
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5981507A (en) 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2271135A1 (en) 1996-11-12 1998-05-22 Medivir Ab Nucleosides
NZ510811A (en) * 1998-10-16 2003-06-30 Schering Corp Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6403564B1 (en) * 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
US6673775B2 (en) 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection

Also Published As

Publication number Publication date
AR031572A1 (en) 2003-09-24
US6924270B2 (en) 2005-08-02
WO2001081359A1 (en) 2001-11-01
US20050004053A1 (en) 2005-01-06
US20020055473A1 (en) 2002-05-09
EP1282632A1 (en) 2003-02-12
US7115578B2 (en) 2006-10-03

Similar Documents

Publication Publication Date Title
AU2001255495A1 (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
AU1197600A (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
HK1041440A1 (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
WO2002032414A3 (en) Ribavirin-pegylated interferon alfa hcv combination therapy
DE60212048D1 (en) Catheter with improved distal pushing ability
AU4806600A (en) Medical suction valve
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2002321888A1 (en) Medical needle
AU2001265173A1 (en) Flexible endodontic syringe
AU2001234425A1 (en) Multi-lumen medical device
AU2002220268A1 (en) Anti-drawback medical valve
AUPQ893200A0 (en) Medical residue treatment
AU2002254724A1 (en) Dual-profile steerable catheter
AU2001232360A1 (en) Medical instrument
AU2001245528A1 (en) Steerable catheter
AU2002222853A1 (en) Therapeutic compounds
AU2002303502A1 (en) Improved leads for the treatment of patients with chf
AU2002355230A1 (en) Blood dialyzer
HUP0200447A2 (en) Ribavirin-interferon alfa combination theory for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
AU2001243299A1 (en) Luminescent medical bandage
AU2001243515A1 (en) Combination drug therapy
AU2001236956A1 (en) Orthogonal arterial catheter
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
MXPA03006412A (en) Methods of administering epothilone analogs for the treatment of cancer.